August 8, 2023: Lessons on Intervention Delivery and Complexity Shared at the Annual Steering Committee Meeting

Headshots of Dr. Steven George, Dr. Vincent Mor, and Dr. Angelo Volandes
From left: Dr. Steven George, Dr. Vincent Mor, and Dr. Angelo Volandes

In an interview at this year’s NIH Pragmatic Trials Collaboratory Steering Committee annual meeting, Drs. Steven George, Vincent Mor, and Angelo Volandes discussed the complexity of intervention delivery in pragmatic clinical trials and the impact it can have on researchers’ ability to discern trial results.

“Without delving deeply into the way in which an intervention can be integrated into an operating system in all of its detail, you will probably make a mistake, and that mistake can impact whether or not your intervention achieves its intended results,” Mor said.

Intervention delivery complexity should be considered early on for pragmatic trials. It is shaped by such factors as new workflows, special training of frontline staff, and the number of components in the intervention.

“We need to understand how we get from point A to point B to point Z, and that’s not something that we do in traditional efficacy trials,” said Volandes.

To characterize this complexity, the NIH Pragmatic Trials Collaboratory worked with its NIH Collaboratory Trial investigators to understand critical drivers of complexity that affected investigators’ ability to implement their interventions and discern treatment effects. The resulting Intervention Delivery Complexity Calculator addresses 6 domains:

  • Internal factors pertain primarily to the intervention itself:
    • The degree to which the intervention requires reengineering of existing workflows and tasks
    • The number of components in the intervention
    • The level of familiarity or extra training needed for those delivering the intervention
  • External factors are related to intervention delivery at the systems level:
    • The degree to which intervention delivery is dependent on the setting in which it is implemented
    • The number of healthcare systems and clinics involved in delivering the intervention
    • The number of steps between the intervention and the intended outcome

Development of the tool was described in a recent article in Contemporary Clinical Trials.

“We as investigators probably don’t think enough about how health systems operate,” Mor said. “Thinking about intervention delivery complexity can help us start to think about things from an operations context.”

The new tool will be used as part of onboarding trials in the NIH Pragmatic Trials Collaboratory and the National Institute on Aging’s IMPACT Collaboratory, which is focused on pragmatic trials for people living with dementia. The tool can be used during the trial review and funding process all the way through sustainability efforts after a trial has been completed.

George explained, “Intervention delivery complexity is strongly linked to sustainability efforts. Even if you can implement an embedded intervention as part of a trial, if it has a lot of external domain complexity, the intervention could be vulnerable after the trial is completed.”

“By understanding the complexity of intervention delivery, investigators could start thinking about scaled down versions of an intervention, which could help with sustainability,” he added.

The tool was developed to enable conversations with investigators and their teams to think through delivery of the intervention, identify the most complex domains, and consider whether something can be done to reduce complexity.

“The tool moves the idea of complexity regarding delivery of the intervention from something that was an abstract concept to something with structure,” George said.

Future versions of the tool could address the relationship between intervention complexity and adaptations in trials to explore impacts on implementation outcomes. More complex interventions may require a greater number of adaptations to be implemented. Sources of adaptation can include service setting adaptations, target audience adaptations, and mode of delivery adaptations, but there is little understanding about who is making the changes and why.

For more information, see the Intervention Delivery and Complexity chapter of the Living Textbook.

September 20, 2021: Vince Mor to Present on Challenges to Implementing Innovative Programs in Long-Term Care

Photo of Vincent Mor
Dr. Vincent Mor, Co-PI of PROVEN

Dr. Vince Mor, a longtime NIH Collaboratory investigator, will present “Challenges Implementing Innovative Programs in Long Term Care: Examples From Pragmatic Trials” at IMPACT Grand Rounds. Join the grand rounds session on Wednesday, September 22, 2021 from 12:00 to 1:00 pm ET.

From the IMPACT Collaboratory announcement:

Vincent Mor, PhD, is a professor of health services, policy & practice and Florence Pirce Grant Professor in the Brown University School of Public Health, and has been principal investigator of 40+ NIH-funded grants focusing on use of health services and outcomes of frail and chronically ill people. He has evaluated the impact of programs and policies including Medicare funding of hospice, changes in Medicare nursing home payment, and the introduction of nursing home quality measures. He co-authored the Congressionally-mandated Minimum Data Set (MDS) and was architect of an integrated Medicare claims and clinical assessment data structure used for policy analysis, pharmaco-epidemiology and population outcome measurement. Dr. Mor developed summary measures using MDS data to characterize residents’ physical, cognitive and psycho-social functioning. These data resources are the heart of Dr. Mor’s NIA- funded Program Project Grant, “Changing Long Term Care in America,” which examines the impact of Medicaid and Medicare policies on long-term care. These data are also at the core of a series of large, pragmatic cluster randomized trials of novel nursing home-based interventions led by Dr. Mor.

Dr. Mor was a co–principal investigator of the Pragmatic Trial of Video Education in Nursing Homes (PROVEN), an NIH Collaboratory Trial. He now serves as a principal investigator of the IMPACT Collaboratory, a program funded by the National Institute on Aging to build the nation’s capacity to conduct embedded pragmatic clinical trials for people living with dementia and their care partners.